Delving into the Latest Updates on SYN021 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Intech Biopharm Ltd.

Active Organization

Intech Biopharm Ltd.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

OBJECTIVETo investigate the effect of three translational enhancers for enhancing transgene expression in baculovirus expression vector system using GFP as a reporter gene and selected translational enhancers to increase porcine circovirus type 2 (PCV2) VLPs production.RESULTSP10UTR (the 3'-untranslated region from the baculovirus p10 gene), Syn21 (a synthetic AT-rich 21-bp sequence) and P10UTR/Syn21 increased the GFP yield by 1.4-, 4- and 4.8-fold, respectively. While IVS (intron from Drosophila myosin heavy chain gene) decreased the GFP yield by 65%. Moreover, the synergy of P10UTR/Syn21 increased the yield of PCV2 VLPs by 4.1 fold (45 μg/10(6) cells) compared with standard baculovirus vector.CONCLUSIONThe synergy of P10UTR/Syn21 is a potential strategy to improve the recombinant vaccine production besides PCV2 VLPs in BEVS.

100 Deals associated with SYN021

Login to view more data